RiboBio provides world-leading oligonucleotide-based drug technology platform and CDMO/CMO solutions, serving customers with comprehensive, highly customized, high-level nucleic acid drug discovery, process and analytical development, CMC services, API production and pharmaceutical registration, allowing partners to accelerate the commercialization and marketing process, and save time and cost with accurate plans. We aim to forge extensive and in-depth cooperation with global pharmaceutical companies, and bring more innovative nucleic acid drugs to the clinic and market and benefit the world.

RiboBio has the largest GMP oligonucleotide API base in Asia, with a planned production of over 20,000 square meters, including 2,700 square meters of production workshop, 2,500 square meters of aseptic filling and finish, with up to 1.8 Mole synthesis scale, up to 4,000L/h purification processing, up to 20Kg lyophilized powder in a single production batch. The quality standard exceeds ICH, the US-FDA, China-NMPA and customer requirements. We apply multiple production suits to meet your needs and  larget capacity allowing for rapid delivery.

Our registered experts with years of experience in drug registration and in-depth knowledge of Chinese and international regulations can deliver professional services for drug registration. Our services include:

● CMC guidance in line with ICH, CFDA, FDA, EMA and other government regulations.
● Worldwide drug registration application, clinical trial application, registration and commercial authorization application.
● Effective project management and registration to ensure correct and timely preparation of registration documents.

To this end, we keep close watch on the regulation system worldwide to speed both in China and other markets, and to overcome possible regulatory and technical obstacles.